CSPC Pharma's SYH2051 Combined with Irinotecan Liposome Enters Phase Ib/II Clinical Trial for Advanced Solid Tumors, First Site Launched in China

Stock News
Yesterday

CSPC PHARMA (01093) has announced that the Phase Ib/II clinical trial of its developed SYH2051 combined with irinotecan liposome for the treatment of advanced solid tumors has officially been initiated at the first research site in China.

The product is a highly selective inhibitor of ataxia-telangiectasia mutated (ATM) protein kinase, registered as a Class 1 chemical drug. It selectively inhibits the activity of ATM kinase, a core component of the cellular DNA damage repair system, thereby preventing DNA damage repair in tumor cells.

The clinical trial now launched is a multicenter, open-label Phase Ib/II study designed to enroll patients with advanced solid tumors, aiming to evaluate the safety and efficacy of the product in combination with irinotecan liposome.

Currently, participant recruitment and screening for this clinical trial are being actively advanced.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10